Xiaoyi Yuan, Ph.D.

University of Texas Health Science Center at Houston
Evaluating Role of MicroRNA as Therapeutic Target for ARDS

Approximately 200,000 patients develop acute respiratory distress syndrome (ARDS) annually in the United States, leading to 75,000 deaths. In ARDS, fluid leaks into the lungs, making breathing difficult or impossible. There are no effective treatment or prevention strategies for this deadly disease. We have found that a group of small gene pieces called microRNAs are crucial molecules in changing the levels of inflammation in lung injury. We will study the role of a microRNA called miR-147 in lung inflammation in ARDS. We will evaluate whether these small genes can be targeted for ARDS treatment safely and efficiently in preclinical studies. Our study will lay the groundwork for novel therapeutic approaches for treating patients with ARDS.

Better Breather Club | Riverside Shore Memorial Hospital
Nassawadox, VA | Mar 26, 2020
Better Breather Club | Riverside Tappahannock Hospital
Tappahannock, VA | Mar 26, 2020